The chance of survival for people with ARS decreases with increasing radiation dose. Most people who do not recover from ARS will die within several months of exposure. The cause of death in most cases is the destruction of the person’s bone marrow, also referred to the Hematopoietic Syndrome of ARS (HSARS).
Neumedicines has demonstrated that low doses of HemaMax™ (rHuIL-12) administered 24 hours after irradiation can rescue animals from otherwise lethal doses of radiation. To support the R&D of this program, Neumedicines has, to date, secured approximately $64 million in contract revenue from the Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, aimed to support the research and development of HemaMax™ to treat HSARS. The HemaMax™-HSARS program is being conducted under the FDA Animal Rule (21 CFR 601.90-95).
Neumedicines hypothesizes and has demonstrated in preclinical investigation that the administration of HemaMax™ after radiation exposure, including time points of 24 hours or longer, provides significant regenerative function for the human hematopoietic system by not only mitigating the bone marrow damage caused by acute ionizing radiation, but also as a therapeutic that is capable of complete regeneration of multilineage hematopoiesis following lethal radiation.
For more information on Acute Radiation Syndrome visit: www.bt.cdc.gov/radiation/ars.asp
HemaMax™ (rHuIL-12) for Surgical Wound Infections (SWI)
HemaMax™ (rHuIL-12) for Cutaneous T-Cell Lymphona (CTCL)
HemaMax™ (rHuIL-12) for Relapsed/Refractory diffuse Large B-Cell Lymphona (DLBCL)